Clinical Study on the Efficacy and Safety of Disitamab Vedotin Combined With Tislelizumab and Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Cancer With HER2 Overexpression
Latest Information Update: 23 Aug 2024
At a glance
- Drugs Capecitabine (Primary) ; Disitamab vedotin (Primary) ; Tislelizumab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
Most Recent Events
- 23 Aug 2024 New trial record